Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial)

Infection

Volumn 45, Issue 2, 2017, Pages 139-145

  Correa Barcellos, Franklin ^a   Pereira Nunes, Bruno ^b   Jorge Valle, Luciana ^a   Lopes, Thiago ^a   Orlando, Bianca ^a   Scherer, Cintia ^a   Nunes, Marcia ^a   Araújo Duarte, Gabriela ^a   Böhlke, Maristela ^a  

^a CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Catheter related bloodstream infection; Citrate; Hemodialysis; Lock solutions

Indexed keywords

CITRATE TRISODIUM; HEPARIN; ANTICOAGULANT AGENT; CITRIC ACID;

ADULT; ARTICLE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEVICE FAILURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SOLUTION; EVENT FREE SURVIVAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; JUGULAR VEIN; LOCK SOLUTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ADVERSE EFFECTS; AGED; BLOOD CLOTTING; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERIZATION; DRUG EFFECTS; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CITRATES; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84984653798     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0929-4     Document Type: Article

References (34)

1. Mills KT, Xu Y, Zhang W, Bundy JD, Chen SC, Kelly TN, Chen J, He1 J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int Adv Online Publ, Kidney Int. 2015 Jul 29. doi:10.1038/ki.2015.230. (Epub ahead of print)
2. Zoccali C, Kramer A, Jager KJ. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant. 2010;25:1731–3.
3. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, Rayner HC, Saito A, Sands JJ, Saran R, Gillespie B, Wolfe RA, Port FK. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis. 2009;53:475–91.
4. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in US hemodialysis patients. Kidney Int. 2001;60:1443–51.
5. Pisoni RL, Zepel L, Port FK, Robinson BM. Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am J Kidney Dis. 2015;65:905–15.
6. US Renal Data System. Annual data report: An overview of the epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
7. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302:1782–9.
8. James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR, Alberta Kidney Disease Network. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med. 2008;148:596–605.
9. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis. 2008;47:83–93.
10. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW. A metaanalysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis. 2008;51:233–41.
11. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter- related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant. 2008;23:1666–72.
12. Zhao Y, Li Z, Zhang L, Yang J, Yang Y, Tang Y, Fu P. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis. 2014;63:479–90.
13. Betjes MGH. Prevention of catheter-related bloodstream infection in patients on hemodialysis. Nat Rev Nephrol. 2011;7:257–65.
14. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1–29.
15. Moran J, Sun S, Khababa I, Pedan A, Doss S, Schiller B. A Randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. Am J Kidney Dis. 2011;59:102–7.
16. Winnett G, Nolan J, Miller M, Ashman N. Trisodium citrate 46.7 % selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant. 2008;23:3592–8.
17. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis. 2003;36:1539–44.
18. Weijmer MC, van den Dorpel MA, van de Ven PJG, et al. Randomized, clinical trial comparison of trisodium citrate 30 % and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16:2769–77.
19. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant. 2004;19:1546–51.
20. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM. Trisodium citrate 4 %––an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant. 2007;22:477–83.
21. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4 % locking solution for central venous dialysis catheters––an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007;22:471–6.
22. MacRae JM, Dojcinovic I, Djurdjev O, et al. Citrate 4 % versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol. 2008;3:369–74.
23. Polaschegg HD. Catheter locking-solution spillage: theory and experimental verification. Blood Purif. 2008;26:255–60.
24. Doorenbos CJ, Van den Elsen-Hutten M, Heuven MJ, et al. Estimation of trisodium citrate (Citra-Lock) remaining in central venous catheters after the interdialytic interval. Nephrol Dial Transplant. 2006;21:543–5.
25. Schilcher G, Schneditz D, Ribitsch W, Horina JH, Hoenigl M, Valentin T, Rosenkranz AR, Krause R. Loss of antimicrobial effect of trisodium citrate due to ‘lock’ spillage from haemodialysis catheters. Nephrol Dial Transplant. 2014;29:914–9.
26. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single center randomized controlled trial. Am J Kidney Dis. 2009;53:1034–41.
27. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis. 2006;48:596–605.
28. Filiopoulos V, Hadjiyannakos D, Koutis I, et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. Am J Nephrol. 2011;33:260–8.
29. Schilcher G, Scharnagl H, Horina J, et al. Trisodium citrate induced protein precipitation in haemodialysis catheters might cause pulmonary embolism. Nephrol Dial Transplant. 2012;27:2953–7.
30. National Kidney Foundation KDOQI Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for vascular access. Am J Kidney Dis. 2006;48:S176–322.
31. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunneled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant. 2004;19:670–7.
32. Ponikvar R, Buturović-Ponikvar J. Temporary hemodialysis catheters as a long-term vascular access in chronic hemodialysis patients. Ther Apher Dial. 2005;9:250–3.
33. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int. 2002;61:305–16.
34. Bunker JP, Bendixen HH, Murphy AJ. Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med. 1962;266:372–7.